SGLT2 inhibitors show anti-proliferative effects against certain tumors, by inhibiting glucose uptake in metabolically reprogrammed cancer cells expressing SGLT2; preclinical studies show that the anti-cancer effects of SGLT2 inhibitor therapy are multifactorial, involving several metabolic pathways [287]. This evidence concerns the gene SLC5A2 and cancer.